Clinical information for the 20 patients with acute lymphoblastic leukemia and 13 controls included in the study.

BCP indicates B-cell precursor ALL; T-ALL, T-cell ALL; HeH, high hyperdiploidy; amp(21), amplification of chr 21; HR, high risk; SR, standard risk; IR, intermediate risk; NA, not available.aWhite blood cell count at diagnosis (109/L).bThe NOPHO ALL 2000 protocol was used.cDNA from was available from bone marrow taken from the patients on day 29,50, and/or 106 after the initiation of therapy, all patients were in morphological remission with less than 5% leukemic blasts.本研究中，BCP指代前B细胞急性淋巴细胞白血病（B-cell precursor ALL）；T-ALL指代T细胞急性淋巴细胞白血病（T-cell ALL）；HeH指代高超二倍体（high hyperdiploidy）；amp(21)指代21号染色体扩增（amplification of chr 21）；HR指代高危（high risk）；SR指代标危（standard risk）；IR指代中危（intermediate risk）；NA指代无可用数据（not available）。 a 诊断时白细胞计数（单位：10^9/L）。 b 采用NOPHO ALL 2000治疗方案。 c 本研究可获取患者于治疗启动后第29、50和/或106天采集的骨髓样本的互补DNA（cDNA），所有患者均已达到形态学缓解，骨髓内幼稚白血病细胞占比低于5%。